FDA Flags Eye Risks as Ozempic and Zepbound Use Grows

Eye risks associated with GLP-1 medicines are drawing greater attention as millions of patients use these drugs for diabetes and weight management.

The US Food and Drug Administration (FDA) required new eye-risk information in the labeling of Ozempic, Zepbound, Wegovy and Mounjaro.

The warning highlights a rare condition that can cause sudden vision loss and, in some cases, permanent damage.

As these treatments gain wider use, the decision raises an important question about how patients and healthcare providers can balance treatment benefits with potential complications and strengthen safety monitoring.

What the FDA's New Eye Warning Means for Patients

The FDA's warning concerns non-arteritic anterior ischemic optic neuropathy (NAION), a condition that develops when reduced blood flow affects the front part of the optic nerve. It can cause sudden, painless vision loss, usually in one eye, and may permanently impair sight.

Reuters reported that the FDA reviewed clinical trials, animal studies, observational research, and post-marketing reports before requiring the label changes. The regulator identified a potential increased risk associated with GLP-1 medicines, although the complication remains uncommon.

Key symptoms include:

• Sudden vision loss in one eye
• Blurred vision or unexpected blind spots
• Abrupt changes in eyesight requiring urgent assessment

Also Read: The Rise of Complex Generics and Biosimilars: 2026 & Beyond

Why GLP-1 Drug Safety Needs Closer Attention

The new warning adds another consideration to treatment decisions as Ozempic and Zepbound gain popularity. However, it does not establish that GLP-1 medicines are unsafe overall or that every patient faces the same risk.

Drugmakers have also highlighted differences in their interpretation of the available evidence. Eli Lilly said the FDA communication applies to all medicines with GLP-1 receptor agonist activity and does not identify findings specific to its products.

Novo Nordisk maintained that existing data do not establish a cause-and-effect relationship and expressed confidence in its medicines' benefit-risk profile.

For patients, the immediate priority remains informed treatment and timely medical attention.

• Seek immediate medical care for sudden vision changes.
• Discuss concerns about treatment risks with healthcare providers.
• Avoid stopping prescribed medication without medical advice.

Ultimately, the FDA's warning reinforces the need for continued safety monitoring as GLP-1 medicines expand their role in diabetes and obesity care.